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Abstract
Although magnetic resonance-guided focused ultrasound (MRgFUS) is a viable treatment option for essential tremor, some
studies note a diminished treatment benefit over time. A PubMed search was performed adhering to Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were included if hand tremor scores (HTS),
total Clinical Rating Scale for Tremor (CRST) scores, or Quality of Life in Essential Tremor Questionnaire (QUEST)
scores at regular intervals following MRgFUS treatment for essential tremor were documented. Data analyses included a
random effects model of meta-analysis and mixed-effects model of meta-regression. Twenty-one articles reporting HTS for
395 patients were included. Mean pre-operative HTS was 19.2 ± 5.0. Mean HTS at 3 months post-treatment was 7.4 ± 5.0
(61.5% improvement, p < 0.001). Treatment effect was mildly decreased at 36 months at 9.1 ± 5.4 (8.8% reduction). Metaregression of time since treatment as a modifier of HTS revealed a downward trend in effect size, though this was not statistically significant (p = 0.208). Only 4 studies included follow-up ≥ 24 months. Thirteen included articles reported total CRST
scores with standardized follow-up for 250 patients. Mean pre-operative total CRST score decreased by 46.2% at 3 months
post-treatment (p < 0.001). Additionally, mean QUEST scores at 3 months post-treatment significantly improved compared
to baseline (p < 0.001). HTS is significantly improved from baseline ≥ 24 months post-treatment and possibly ≥ 48 months
post-treatment. There is a current paucity of long-term CRST and QUEST score reporting in the literature.
Keywords Essential tremor · Focused ultrasound · MRgFUS · Thalamotomy · Meta-analysis

Introduction
Essential tremor (ET) is a relatively benign condition characterized by an idiopathic, progressive tremor of the upper
extremities [17]. Yet, patients suffering from ET (particularly medication-refractory ET) report debilitation and
embarrassment and have high concomitant rates of depression and anxiety [20, 31, 44]. Thus, patients seek treatment
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to improve daily life. First-line treatment includes medications such as propranolol and primidone [17]. If medical
management fails, patients may be referred for radiofrequency thalamotomy, gamma knife thalamotomy, or deep
brain stimulation (DBS). These procedures are relatively low
risk, but the associated adverse events can be severe (e.g.,
hemiparesis, paresthesias, and intracranial hemorrhage) [11,
26, 43]. Additionally, DBS electrode placement requires skin
incision and confers risk of soft tissue infections and hemorrhage [11, 26]. Approved by the United States Food and
Drug Administration (FDA) in 2016, magnetic resonanceguided focused ultrasound (MRgFUS) is a stereotactic
modality that mitigates many surgical risks. However, the
long-term benefit of this treatment remains undetermined.
Ultrasound is gaining favor across many medical specialties for its low cost, availability, and lack of ionizing radiation. Previous inability of ultrasound to traverse the calvarium traditionally limited its utility in neurosurgery; however,
advanced algorithms coordinate multiple emission points via
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a phased transducer array to enable ultrasound waves to be
effectively focused through bone to a single anatomic location [24]. The kinetic energy of focused ultrasound waves
elevates tissue temperature and causes cell death within a
well-defined lesion. Magnetic resonance targeting of focused
ultrasound confers significant lesioning accuracy. Additionally, MRgFUS does not require craniotomy, skin incision,
or general anesthesia, and thereby minimizes surgical complications, recovery periods, and resource utilization [18].
Despite these advantages, MRgFUS has several notable
weaknesses. MRgFUS thalamotomy is only FDA approved
for unilateral treatment of essential tremor. This limitation
is intended to prevent serious adverse effects, though bilateral MRgFUS thalamotomy is performed (in small samples) safely and effectively for research [1, 21]. A series of
stereotactic thalamotomy describes persistent dysarthria in
6% of unilateral procedures and 27% bilaterally, suggesting an effect-modifying relationship. Interestingly, a recent
meta-analysis by Giordano et al. describes a similar value of
speech disturbances (5.5%) for unilateral focused ultrasound
thalamotomies [13]. Giordano et al.’s comparisons of unilateral DBS and MRgFUS showed no significant difference
in treatment effect but a difference was observed between
unilateral MRgFUS and bilateral DBS. Additionally, thalamotomy is a static and permanent procedure, whereas DBS
electrodes may be adjusted or turned off as needed. Patients
with low skull density ratios (SDR) may not benefit from
MRgFUS due to ultrasound wave impedance. The American Society for Stereotactic and Functional Neurosurgery
listed SDRs < 0.4 as a contraindication to MRgFUS in their
position statement published December 2019 [40]. Interestingly, data published the same year suggests that SDR is a
poor predictor of MRgFUS outcome and that skull shape
and volume are more relevant indicators of patient response
[2, 5, 6].
Initial reports suggest a possibly diminished effect of
MRgFUS after greater follow-up periods. This decrease
may be clinically important and especially apparent between
3 months and 1 year post-operatively [8, 9, 28, 46]. Several scales have been designed to measure efficacy of treatment and quality of life in patients suffering from ET. The
Clinical Rating Scale for Tremor (CRST) is a reliable and
sensitive tool for evaluating ET severity [7]. CRST consists
of part A (assessing global tremor severity), part B (action
tremors of the upper extremity), and part C (tremor interference with daily activities). Hand tremor score (HTS) is
a modified 32-point score derived from parts A and B of
the CRST. HTS is used to standardize the pre- and postoperative evaluation of hand-specific ET symptoms [9]. The
Quality of Life in Essential Tremor Questionnaire (QUEST)
score is a standardized number that quantifies ET’s impact
on patient well-being. Though QUEST scores are subjectively dependent on an individual patient’s experience, they
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are an important tool for evaluating ET severity, particularly
before and after treatment [7]. Previously published metaanalyses did not evaluate MRgFUS effects beyond 1 year.
Therefore, existing evaluation of treatment efficacy beyond
1 year is limited to individual studies.
Our primary goal is to evaluate the prevalence of worsening tremor after treatment with MRgFUS via longitudinal analysis of CRST, QUEST, and HTS metrics. We pool
reported effects at commonly reported follow-up time points
and utilize a meta-regression technique to explore long-term
trends. To our knowledge, this is the first meta-analysis to
include several years of follow-up data. Our results are
intended to inform movement disorder specialists and neurosurgeons when selecting appropriate treatment modalities
for medication-refractory ET.

Materials and methods
Database query and study selection
We searched the PubMed database using the search string
“("magnetic resonance guided focused ultrasound" OR
"MRgFUS" OR "focused ultrasound") AND ("essential
tremor").” We followed Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines
for meta-analysis [36] to systematically review titles, then
abstracts, and eventually full texts of returned articles based
on the following inclusion criteria:
1) At least some of the reported data must describe patients
who received MRgFUS treatment for patients with a
diagnosis of ET.
2) The data for ET patients must be presented separately
from the data for patients with other included diseases
(chiefly, Parkinson’s disease).
3) Reported relevant data must include total CRST scores,
QUEST scores, or HTS prior to and at regularly scheduled intervals after MRgFUS lesioning.
4) Data must be presented alongside measures of variance
to enable calculation of Hedges’ g as a measure of effect
size.
Only one report from studies with multiple associated
publications was included in the analyses at each time point,
to eliminate duplicated data. For these studies, data was only
included if separate cohorts or time points were distinct from
other overlapping studies. We relied on clear author disclosure of association, identical reported values with common
authors, and database searches for reported clinical trial
associated publications to identify studies with multiple publications. Several studies reported “hand tremor scores” that
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were not consistent with the previously described 32-point
scale. We excluded these studies from the analysis.

Statistical analysis

Results
Literature search
Details of our literature search may be reviewed in Fig. 1.
Our literature search returned 173 articles from the PubMed
database. Examination of sources cited in other studies identified 4 additional publications meeting inclusion criteria.
The abstract/title review eliminated 123 articles; 54 articles
underwent subsequent full-text review. Final meta-analyses
included 21 articles. A failure to report data in a usable
format or reporting of HTS/CRST/QUEST scores without
corresponding pre-MRgFUS controls eliminated 21 studies. Additionally, our search identified 2 studies focusing on
Parkinson’s disease rather than ET. Poorly defined follow-up
periods for individual patients eliminated 1 additional study,
as this prevented data aggregation into precise time points
for meta-analysis. Failure to report standard deviations

Records idenfied through
database searching
(n = 173)

Addional records idenfied
through other sources
(n = 4)

Eligibility

Screening

Records aer duplicates removed
(n = 177)

Records screened
(n = 177)

Full-text arcles assessed
for eligibility
(n = 54)

Studies included in
qualitave synthesis
(n = 21)

Included

Fig. 1  Displays the PRISMA
flow-chart describing the
results of the literature search
performed

Idenficaon

Statistical analyses were conducted using the R programming language and software environment for statistical computing and graphics (R core team 2013). We grouped and
separated data based on follow-up time points and clinical
scales (HTS, CRST, QUEST). Means and standard deviations of clinical scale values were pooled via the method
included in Cochrane Handbook for Systematic Reviews
of Interventions (“7.7.3.8 Combining Groups”), separate
from our random effects model [19]. For the random effects
model, all MRgFUS treatment effect sizes were calculated
from reported data as the standardized mean difference
(Hedges’ g) at 3 months, 12 months, and 24 months postoperatively where data and statistical power permitted.
We estimated between-study variance using the DerSimonian-Laird method and between-study heterogeneity using
Cochran’s Q (χ2) and I2 values. Univariate meta-regression
was performed using a mixed-effects model to evaluate
whether time since MRgFUS treatment (in months) is a
significant moderator of treatment effect size. Meta-regression was performed for HTS values from 3 to 48 months

post-treatment, as well as for a sub-cohort of HTS values
from 12 to 48 months post-treatment. Meta-regression was
not performed for CRST and QUEST values due to lack of
long-term data (≥ 12 months follow-up) for these values. P
values ≤ 0.05 were considered significant.

Records excluded
(n = 123)

Full-text arcles excluded
(n = 33)
No CRST score or unusable format
(n = 21)
Meta-analysis/review (n = 6)
Parkinson’s Disease (n = 2)
Issues with follow up (n= 2)
Discrepancies in Data (n=1)
Language (n=1)

Studies included in
quantave synthesis
(meta-analysis)
(n = 21)
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with CRST scores and minor discrepancies between values reported in the manuscript body and study tables also
excluded 1 study each. Two studies reported hand tremor
scores inconsistent with the 32-point scale outlined in our
methods; of these, 1 study reported total CRST scores which
permitted its inclusion in total CRST analysis only.
Of the studies included, one (Elias et al. 2016) was a
prospective, randomized controlled trial representing level
II evidence. Twenty studies used pre-treatment values as
controls; seventeen were prospective and three were retrospective, each representing level III evidence [32]. Papers
included featured primary authors (in alphabetical order)
from Argentina, Canada, Israel, South Korea, Spain, Switzerland, and the USA.

Baseline information
The baseline and demographics data from included studies
is displayed in Table 1. The analysis included 395 patients
after removal of duplicate data. The majority of treated
patients were male (70%). The mean age of treated patients
was 70.2 ± 8.9 years and the mean symptom duration before
MRgFUS treatment was 21.2 ± 16.9 years. During MRgFUS
treatment, the mean maximum peak tissue temperature was
56.5 ± 2.5 °C and the mean peak energy was 15.57 ± 7.4 kJ.

Hand tremor scores
Six studies reported HTS follow-up data after 3 months,
9 studies after 12 months, and 4 studies after 24 months
(Table 2). After removal of duplicate data, we included
8 studies at the 12-month time point and 3 studies at the
24-month time point. Weighted mean pre-operative HTS
values (19.2 ± 5.0) decreased to 7.4 ± 5.0 after 3 months;
subsequently, weighted mean HTS increased to 7.8 ± 4.9
after 6 months, 8.3 ± 5.3 after 12 months, 9.0 ± 5.3 after
24 months, and 9.1 ± 5.4 after 36 months. Halpern et al. and
Park et al. each reported 36 months of follow-up data, but
only Park et al. published HTS data at the 48-month time
point (7.7 ± 4.1). This 48-month value is lower than our calculated HTS means for earlier time points but is elevated
over their reported intra-study values for earlier time points.
The crossover and sham procedure arms of Elias’ 2016
study and follow-up studies (Chang and Halpern) are
included in this table. However, these studies (denoted by
*) were not included in meta-analyses at overlapping followup times. Similarly, these values were not used in calculating
the pooled mean and standard deviations.
The pooled standardized mean difference of the random
effects model (overall effect) compared to pre-treatment HTS
values was 2.68 (95% CI: 1.94–3.41; χ2 = 19.34, p < 0.01)
at the 3-month time point, 2.44 (95% CI: 1.97–2.91;
χ2 = 17.31, p < 0.01) at the 12-month time point, and 2.18
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(95% CI: 1.50–2.86, χ2 = 5.77, p = 0.06) at the 24-month
time point (Fig. 2A–C). All p values for pooled effects
were < 0.001, indicating a significant difference in HTS from
baseline to follow-up at all analyzed time points. Calculation
of Cochran’s Q-statistic (χ2) suggested significant betweenstudy heterogeneity at both the 3- and 12-month time points
(p < 0.01). χ2 was not significant at the 24-month time point
(p = 0.06), but this measure is significantly dependent on
sample size, which was quite small for this time point (4
individual studies, n = 146 patients). I2 values further supported moderate to significant heterogeneity at all time
points (65–79%) (Fig. 2).
We conducted meta-regression analysis of HTS values
to further investigate a correlation between MRgFUS effect
size and time from 3 to 48 months post-treatment (Fig. 3).
Univariate analysis suggested a statistically non-significant
trend of decreased effect size (Hedges’ g) with increased
follow-up times (p = 0.208). A separate meta-regression
investigating effect size trend from 12 to 48 months posttreatment revealed a similar result and failed to demonstrate
a statistically significant correlation (p = 0.489). This subcohort analysis was performed to assess sustained effects
specifically after the 12-month time point as suggested by
recent literature [33].

Total CRST scores
Nine studies reported follow-up total CRST scores at the
3-month time point, 5 studies at the 6-month time point,
and 6 studies at the 12-month time point (Table 3). No
included studies reported total CRST scores after 12 months.
The pooled mean for pre-operative total CRST scores was
53.6 ± 16.3 which decreased to 28.8 ± 13.6 at 3 months. Contrary to HTS, a diminished effect from 3 months followup was not observed in the mean CRST values at 6 and
12 months (25.7 ± 15.5 and 26.8 ± 14.6, respectively).
The pooled standardized mean difference of the random effects model (overall effect) of the total CRST scores
was 1.86 (95% CI: 1.51–2.21; χ 2 = 10.25, p = 0.17) after
3 months and 2.24 (95% CI: 1.55–2.94; χ2 = 21.79, p < 0.01)
after 12 months (Fig. 2D–E). Again, pooled effect sizes were
significant for both 3- and 12-month periods (p < 0.001),
indicating a significant difference between pre- and postMRgFUS total CRST scores.

QUEST scores
Six studies reported QUEST scores as a quality of life
measure in patients with ET (Table 4). Pooled pre-operative QUEST score was 48.2 ± 22.4 which improved to
24.9 ± 18.2 at 3 months. The pooled standardized mean
difference of our random effects model (overall effect)
of QUEST scores at 3 months follow-up was 1.67 (95%
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Table 1  Displays the baseline and demographic data and their pooled means and standard deviations (not from our random effects model)
Mean peak
energy
(KJoules)

Study

Mean age
(years)

N=

Prospective/
retrospective

Lesion site

% male Symptom
duration
(years)

Mean
sonication
number

Mean peak
temperature
(°C)

Lipsman
2013 [30]
Elias 2013 [8]
Wintermark
2014 [47]
Wintermark
2014 [48]
Gallay 2016
[12]
Elias 2016 [9]
Crossover/
Sham
Zaroor 2018
[49]
Federau 2018
[10]
Chang, JW
2018 [4]
Harary 2018
[15]
Iacopino
2018 [22]
Jung 2018
[25]
Krishna 2019
[27]
Tian 2018
[46]
Meng 2018
[33]
Boutet 2018
[3]
Park 2019
[37]
Pineda-Pardo
2019 [39]
Miller 2019
[34]
Krishna 2019
(post-pivotal
cohort only)
[29]
Halpern 2019
[14]
Total/mean

70.8 ± 9.0

4

Prospective

ViM

100

17.8 ± 8.2

22.5 ± 7.6

59.3 ± 2.9

66.6 ± 8.0
67 ± 8.0

15
15

Prospective
Prospective

ViM
ViM

66.7
66.7

32 ± 21.3

17.9 ± 4.6
18

58.5 ± 2.5
59 ± 3.0

67 ± 8.0

14

Prospective

ViM

66.7

69.1 ± 9.2

21

Prospective

CTT

71

29.9 ± 15.0

70.8 ± 8.7
71.4 ± 7.3

56
20

Prospective*

ViM

66
75

28.3 ± 16.4
27.9 ± 14.9

18.5 ± 5.2
N/A

55.6 ± 2.2
N/A

14.50 ± 6.70

68.9 ± 8.3

18

Prospective

ViM

12.1 ± 8.9

21.0 ± 6.9

56.5 ± 2.2

12.50 ± 4.27

78.0 ± 6.0

7

Retrospective ViM

71

71.0 ± 8.3

76

Prospective

ViM

68

16.8 ± 12.3

18.5 ± 5.2

55.6 ± 2.3

14.50 ± 6.70

67.7 ± 6.3

7

Prospective

ViM

71

32 ± 17

65.2 ± 11.9

13

Prospective

ViM

76.9

22.4 ± 22.6

64.1

20

Prospective

ViM

85

21.2

16.8

57.9

15.91 ± 5.70

70.8

10

Prospective

ViM

60

34.3 ± 22.1

13.9 ± 4.5

8

Prospective

ViM

71.4

37

Prospective

ViM

21.6

22.3 ± 14.0

72.4 ± 8.4

66

Retrospective ViM

71

23

61.7 ± 8.1

12

Prospective

ViM

83.3

17.8 ± 13.0

68.0 ± 10.1

24

Prospective

ViM

70.8

18.6 ± 12.8

4

Retrospective DRT

71 ± 9.5

114

Prospective

ViM

70

15.4 ± 13.3

71.0 ± 8.3

75

Prospective

ViM

70.2 ± 8.9

580, 395 with
duplicates
removed

19 ViM, 1
CTT, 1
DRT

10.30 ± 4.55

16.07 ± 6.04

18.6 ± 5.7

56.6 ± 2.3
17.3 ± 1.6

15.55 ± 6.57

17.1 ± 5.3

56.7 ± 2.5

16.91 ± 8.34

17.8 ± 5.4

56.5 ± 2.5

15.40 ± 7.20

16.8 ± 12.3
70

21.2 ± 16.9

CTT = cerebellothalamic tract, DRT = dentato-rubro-thalamic tract, ViM = ventral intermediate nucleus of the thalamus, *represents a randomized, controlled trial.
Only data with standard deviations were included in the mean calculations if standard deviations were calculated. Suspected duplicate data were
also removed from calculations of the mean and standard deviation.
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Table 2  Displays the total hand tremor scores defined for studies meeting inclusion criteria
Study

Pre-op n =

Pre-op

3 months

Elias 2013 [8]
Wintermark 2014* [48]
Elias 2016 [9]
Sham*
Crossover*
Federau 2018 [10]
Chang 2018* [4]
Krishna 2019 [27]
Tian 2018 [46]
Meng 2018 [33]
Krishna (post-pivotal
group) 2019 [29]
Park 2019 [37]
Halpern 2019* [14]
Weighted mean

15
14
56
20
21
6
76
9
8
37
114

20.4 ± 5.2
19.8 ± 5.0
18.1 ± 4.8
16 ± 4.4
16.5 ± 4.2
21.5 ± 2.0
19.8 ± 4.9
18.3 ± 4.5
18.9 ± 2.4
20.3 ± 5.0
19.3 ± 5.0

4.3 ± 3.5
4.6 ± 3.5
9.6 ± 5.1
15.8 ± 4.9
7.43 ± 3.9

12
17.4 ± 3.8
75
20.1 ± 4.7
271 patients (with
19.2 ± 5.0
duplicates removed)

6.5 ± 3.7
9.1 ± 0.9
7.0 ± 5.0

6 months

2 years

3 years

4 years

7.5 ± 5.3
9.5 ± 5.4
9.1 ± 5.4

7.7 ± 4.1

5.2 ± 4.8
10.1 ± 5.3

10.9 ± 4.5

8 ± 3.9

6.71 ± 4.7
9.7 ± 5.2
8.9 ± 4.8

8.6 ± 4.5
11 ± 3.7
7.4 ± 5.0
5 ± 3.3

7.4 ± 5.0

1 year

7.8 ± 4.9

8.8 ± 5.0

11 ± 4.8
11.7 ± 6.6
7.4 ± 4.8

11.5 ± 6.7

5.3 ± 3.4
8.9 ± 4.8
8.3 ± 5.3

6.9 ± 3.6
8.4 ± 5.0
9.0 ± 5.3

7.7 ± 4.1

*Denotes suspected duplicate data which were not included in meta-analyses at overlapping times.

CI:1.09–2.25, χ2 = 9.65, p = 0.05) (Fig. 2F). The p value
for the pooled effect at 3 months was < 0.001, indicating
significant improvement in QUEST score from baseline.

Additionally, Halpern et al. detailed a mean 23.8 ± 19.6
QUEST score at 36 months follow-up, an increase of 2.2
over 30 months.

Fig. 2  Displays forest plots for; 2a. HTS at 3 months, 2b. HTS at 12 months, 2c. HTS at 24 months, 2d. Total CRST score at 3 months, 2e. Total
CRST scores at 12 months and 2f. QUEST scores at 3 months post-operatively compared to baseline scores
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Fig. 3  Displays the metaregression bubble plots depicting the time since treatment
on the X-axis and the effect
size on the Y-axis. Two metaregressions were performed; 3a.
includes measurements from 3
to 48 months (p = 0.208) while
3b. includes only measurements
12–48 months (p = 0.489)

Discussion
Elias et al.’s 2013 pilot study of MRgFUS for ET
unveiled a promising addition to t he functional
n e u ro s u rge o n’s re p e r to i re [ 8] . T h ey h o p e d t h i s
incisionless procedure would prove safer than DBS

Table 3  Displays the overall
CRST scores for each study
with pooled means and standard
deviations (not from our random
effects model)

and current stereotactic modalities while providing
long-term clinical benefit. Although numerous studies have presented MRgFUS to be a relatively safe
procedure, conclusions of sustained efficacy have
been limited by low sample sizes and incongr uent
methods.

Study

Pre-op n =

Pre-op

3 months

Lipsman 2013 [30]
Elias 2013* [8]
Wintermark 2014* [47]
Elias 2016 [9]
Sham*
Crossover*
Gallay 2016 [12]
Zaroor 2018 [49]
Harary 2018 [15]
Iacopino 2018 [22]
Jung 2018 [25]
Krishna 2019 [27]
Boutet 2018 [3]
Pineda- Pardo 2019 [39]
Miller 2019 [34]
Weighted mean

4
15
15
56
20*
21**
13
18
7
13
20
10
66
24
4
250 patients
(with duplicates
removed)

70.8 ± 19.7
54.9 ± 14.4
54.9 ± 14.4
50.1 ± 14.0
44.1 ± 12.7
45.4 ± 12.6
57.6 ± 13.2
40.7 ± 11.6
51.4 ± 10.8
40.2 ± 11.8
44.8 ± 9.6
59.3 ± 17.3
59.7 ± 17.4
52.9 ± 13.0
57.5 ± 16.8
53.6 ± 16.3

35.3 ± 11.0
20.3 ± 11.0
29.6 ± 13.0
43.1 ± 13.1
23.5 ± 11.0

19.3 ± 10.1
17.3 ± 7.3
29.0 ± 16.0
34.8 ± 14.4
23.8 ± 8.3
29.5 ± 6.4
28.8 ± 13.6

6 months

1 year
24.3 ± 14.8

31.7 ± 14.4

32.4 ± 14.5

25.0 ± 11.1

18.7 ± 16.0
25.8 ± 17.6

8.2 ± 5.0
20.1 ± 7.4
17.7 ± 8.8
32.0 ± 15.9

24.9 ± 11.0
14.7 ± 9.2

26.4 ± 11.3
25.2 ± 15.5

26.8 ± 14.5

*Denotes suspected duplicate data that was not included in the analysis of this paper.
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Table 4  Displays the QUEST score data included in studies
Study

Pre-op n =

Pre-op

3 months

Elias 2016* [9]
Sham*
Zaroor 2018 [49]
Harary 2018 [15]
Iacopino 2018 [22]
Krishna 2019 [27]
Halpern 2019 [14]
Weighted mean

56
20
18
7
13
10
75
123 patients (with
duplicates removed)

42.6 ± 18.3
42.8 ± 19.5
44.8 ± 12.9
88.7 ± 20.5
35.1 ± 12.3
81.7 ± 17.7
43.1 ± 18.3
48.2 ± 22.4

23.1 ± 16.9
41.4 ± 19.4

17.1 ± 10.7
45.3 ± 11.6
24.9 ± 18.2

6 months

1 year

2 years

3 years

22.9 ± 19.6
22.9 ± 19.6

23.8 ± 19.6
23.8 ± 19.6

21.7 ± 17.2
12.3 ± 7.2

45.6 ± 10.8
21.6 ± 17.6
24.7 ± 17.2

55.4 ± 22.1

20.0 ± 17.2
23.2 ± 20.3

Means and standard deviations were pooled and are not a result of our random effects model. Elias et al.’s sham procedure cohort is included for
comparison but was not included in any calculations.
*Denotes suspected duplicate data that was not included in the analysis of this paper.

MRgFUS efficacy
Our analysis revealed a diminished effect from 3 to 12 and
24 months post-treatment (standardized mean difference
of 2.68 to 2.44 and 2.18, respectively). Notably, Hedges’ g
(standardized mean difference) value is dependent on the
standard deviation. Therefore, while the diminished effect
above may seem large based on sample size (i.e., patients
lost to follow-up), changes in individual outcomes may be
less profound. Meta-regression illustrates a trending decrease
(p = 0.208) which suggests a decreased treatment effect with
time. Care should be taken when interpreting this trend; the
insignificant p value indicates that time elapsed since treatment is not an accurate predictor of treatment effects but does
not necessarily reflect a lack of decline over time. However,
identification and control of other treatment parameters which
may produce effect heterogeneity (skull shape, age, symptom
duration, etc.) will theoretically enable more accurate analysis. CRST scores likely worsen with time; whether the culprit
is diminished effect or disease progression is debatable. However, treatment benefit compared to pre-treatment symptoms
is apparent at all follow-up times reported.
Elias et al. presented a randomized controlled trial in
2016 that demonstrated the efficacy of MRgFUS[9]; Chang
et al. [4] and Halpern et al. [14] continued to follow this
study cohort at 24 and 36 months post-treatment, respectively. Park et al. provided a separate analysis 48 months
post-treatment [37]. Overall, these studies suggest significant benefit several years post-operatively and a small score
increase with time (approximately 1–2.5 points). Extended
analysis of data originally presented by Elias et al. [9] via
Chang et al. [4] and Halpern et al. [14] is difficult since
initial cohorts were combined in later studies and patients
were lost to follow-up. Two meta-analyses recently compared MRgFUS for ET to other treatment modalities;
Schreglman et al. [43] included radiofrequency and gamma
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knife techniques and Harary et al. [16] studied unilateral
DBS placement. Both studies detail similar initial treatment
effects across modalities, however, neither provide follow-up
in the past 12 months.
Several studies report diminished effects of DBS
over time. Rodriguez et al. report a mean tremor reduction of 71.5% within 6 months that worsened to 50.1%
over ~ 7.5 years mean follow-up [41]. In a study of twenty
patients, Paschen et al. report a mean tremor worsening of
0.37 points per month in CRST scores following DBS [38].
Their study included an interesting analysis of patient’s
CRST scores with stimulators on and off to determine 87%
of decline was due to disease progression, while 13% was a
result of habituation to DBS. Data presented by Park et al.
suggest a 71% HTS reduction at 6 months which declined to
56% at 48 months [37]. Direct comparisons between studies
are limited since they utilized different scores. Further headto-head longitudinal comparisons of these two interventions
past the 12-month time point are necessary.

Treatment parameters
We collected data regarding mean peak tissue temperature,
age, and sonication numbers and performed a meta-regression based on these variables. However, few studies report
uniform data; the model was fundamentally limited and
therefore not included. These analyses are more appropriate for studies with individual patient data. Elias and colleague’s 2016 study [9] accounts for the majority of data
after 12 months, with follow-up data reported by Chang
et al. [4] and Halpern et al. [14], and had a relatively low
mean peak tissue temperature (55.6 ± 2.2). Interestingly,
their data showed a relatively low treatment effect compared
to prior studies. Therefore, long-term follow-up of patients
with higher mean peak tissue temperatures may provide
valuable information.

Neurosurgical Review

Krishna et al. recently analyzed data from 189 patients
treated with MRgFUS (75 from the Elias et al. randomized
trial [9] and 114 from their “post-pivotal” cohort) [28]. They
identified lower sonication number, higher peak temperature,
age, and disease duration as predictors of positive patient outcome. SDR was not a significant predictor and patients in the
post-pivotal group (which experienced more successful outcomes) had a lower SDR (0.50 ± 0.1 vs. 0.55 ± 0.1, p = 0.004).
Post-pivotal patients also experienced a higher number of
adverse events (4 of 114, 3.5%), possibly resulting from
higher tissue temperatures. However, improved outcomes in
their post-pivotal cohort may also result from increased provider experience with MRgFUS. Additionally, higher mean
peak tissue temperatures may reflect improved technology.
Jones et al. published an intriguing analysis of patients
in whom peak temperatures greater than 55 °C could not
be reached [23]. They employed multiple low temperature
(50–54 °C) sonications to reach a goal accumulated thermal
dose. Comparisons to their previous study yielded similar
CRST hand tremor score improvements (notably, we did not
include this study in our analysis due to minor discrepancies
in data). However, they note that patients with the accumulated thermal dose method had smaller lesion volumes,
which Meng et al. [33] correlate with lower improvements in
CRST. Jones et al. suggest long-term follow-up is necessary
to determine if this method is sustainable [23]. However,
their technique may benefit patients traditionally considered
poor candidates for MRgFUS.

Quality of life
Though relatively few studies included QUEST scores, the
pooled effect size was quite large, suggesting MRgFUS significantly improves the quality of life for patients suffering
from ET. We observed a bimodal distribution and large standard deviation of QUEST scores possibly emanating from
their subjective nature (Table 4). Despite the challenges of
subjective assessments, QUEST scores are important to consider since they reflect the patient’s perspective (i.e., how has
treatment improved the patient’s quality of life). Mohammed
et al. report a 46.5% improvement in QUEST scores in their
meta-analysis (later updated to 50.7% post-publication after
corresponding with Schreglman et al.) and 69.1% improvement in CRST part C (details tremor impact on daily activities) [35, 42]. Harary et al. suggest that QUEST scores are
lower in patients undergoing DBS, indicating better quality
of life [16]. Future studies may investigate long-term patient
satisfaction after MRgFUS treatment.

Safety profile
We chose not to perform a meta-analysis of safety profiles
since several meta-analyses already exist [18, 35, 43], and

our primary focus was long-term follow-up. Mohammed
et al. reported paresthesia (25.1%) and ataxia (32.8%) as
common adverse events (AEs) at 3 months follow-up [35].
These percentages decreased to 15.3 and 10.5%, respectively,
at 12 months. Schreglman et al. report persistent AEs after
MRgFUS thalamotomy in 18.7% of patients [43]. Additionally, they analyzed AE rates for radiofrequency and gamma
knife thalamotomy (9.3 and 1.8%, respectively). However,
severe AE rates were lowest in the MRgFUS cohort (1.2%
vs. 9.3% for radiofrequency and 1.8% for gamma knife).
Common perioperative complications of DBS include
headache (4–15.0%), confusion (1.5–6.6%), and hallucinations (0.4–2.8%) [11, 26, 45]. Infection occurs in approximately 3.1–6.6% of cases and may require reoperation in
1.7–2.5% [11, 26]. Therefore, MRgFUS certainly has an
advantage with regard to infection rates but AEs are more
frequent with MRgFUS. Analysis by Harary et al. included
a direct comparison of AEs; DBS resulted in speech and gait
disturbances in 9.4 and 2.4% of cases at 6 months, respectively [16]. Gait disturbances occurred in 16.1% and lasted
at least 12 months in 8.9% of patients undergoing MRgFUS.

Limitations
Our meta-analysis provides valuable insights into the future
of MRgFUS. However, there are several notable limitations
to this study. Many studies did not use uniform tremor scales
or report standard deviations or confidence intervals, which
prevented their inclusion in the pooled analysis. Several studies had overlapping authors and time frames. To the best of
our ability, we did not include multiple studies with obvious
patient overlap. Therefore, if two studies were suspected to
include overlap, we did not include the study with a smaller
sample size in our data analysis. However, these studies were
often difficult to identify. It is possible that we included overlapping patient cohorts in our analyses despite these efforts.
Power analyses of our data reported sufficient power up to
24 months, but meta-regression incorporated data past the
24-month time point. Not all time points were assessed based
upon lack of sufficient reporting in the literature; namely, the
lack of sufficient CRST and QUEST score reporting after
12 months post-treatment. Statistical analysis of differences
in weighted mean HTS, CRST, and QUEST score values
between time points was deferred due to more robust testing through pooled standardized mean difference and metaregression analyses. Additionally, we report high levels of
heterogeneity which reflect accurate modeling of a diverse
population but cloud determination of effect size. We initially
intended to evaluate and incorporate differences in treatment
parameters (sonications, temperature, age, etc.); however,
there was a lack of uniform reporting among studies. In an
effort to address this variance, we utilized a random effects
model of analysis. Defining factors which do predict treatment
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outcomes will enable accurate determination of effect over
time. Finally, meta-analyses provide valuable insights to treatment efficacies at a population level, but little information
applicable to individuals. We urge providers to be cautious
when applying our data to individual patients.

Conclusions
This is the first meta-analysis to examine long-term MRgFUS outcomes at follow-up time points greater than
12 months. We report HTSs are significantly improved from
baseline at all follow-up points up to 24 months post-treatment, and likely up to 48 months post-treatment. Additionally, we found a decreasing trend in HTS over time. Recent
data suggests skull shape, size, and accumulated thermal
dose are predictors of treatment outcome. Treatment effects
may theoretically be maximized by accounting for these variables. Existing data supports the hypothesis that MRgFUS
benefits are sustained for several years.
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